An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission
Open accessAbstract
Recombinant adeno-associated viruses (AAVs) allow rapid and efficient gene delivery to the nervous system, are widely used in neuroscience research, and are the basis of FDA-approved neuron-targeting gene therapies. Here we find that an innate immune response to the AAV genome reduces dendritic length and complexity and disrupts synaptic transmission in mouse somatosensory cortex. Dendritic loss is apparent 3 weeks after injection of experimentally relevant viral titers, is not restricted to a particular capsid serotype, transgene, promoter, or production facility, and cannot be explained by responses to surgery or transgene expression. AAV-associated dendritic loss is accompanied by a decrease in the frequency and amplitude of miniature excitatory postsynaptic currents and an increase in the proportion of GluA2-lacking, calcium-permeable AMPA receptors. The AAV genome is rich in unmethylated CpG DNA, which is recognized by the innate immunoreceptor Toll-like receptor 9 (TLR9), and acutely blocking TLR9 preserves dendritic complexity and AMPA receptor subunit composition in AAV-injected mice. These results reveal unexpected impacts of an immune response to the AAV genome on neuronal structure and function and identify approaches to improve the safety and efficacy of AAV-mediated gene delivery in the nervous system.
AI snapshot
Written from the paper’s full text.
TL;DR
AAV-mediated gene delivery in mouse somatosensory cortex triggers an innate immune response to the AAV genome that reduces dendritic complexity and disrupts excitatory synaptic transmission. Blocking TLR9 around injection preserves dendritic arbors and AMPA receptor subunit composition, implicating unmethylated CpG DNA in the AAV genome as a key trigger.
Key findings
- AAV injection reduced total dendritic length and Sholl intersections in ipsilateral S1 at 21 dpi; a lower dose of AAV8-hSyn-mCherry (2 × 10⁹ vg) was indistinguishable from untreated controls, while AAV1-pCAG-FLEX-EGFP (4.2 × 10⁹ vg) caused similar loss despite no detectable EGFP expression. Dendritic loss was not restricted to capsid serotype, transgene, promoter, or production facility.
- Dendritic loss began by 4 dpi and progressed by 21 dpi; by 70 dpi ipsilateral and contralateral hemispheres were indistinguishable, but contralateral dendrites also showed significant loss versus 4 and 21 dpi, while untreated 18–20-week-old controls showed no significant loss. AAV injection also modestly reduced cortical thickness from 4 to 21 dpi, reduced cell density from 4 to 21 dpi and at 70 dpi, and increased caspase-3 at 21 dpi.
- AAV1-pCAG-FLEX-EGFP reduced mEPSC frequency, increased inter-event interval, and decreased mEPSC amplitude. NASPM blocked 5.1% of sEPSCs in untreated controls versus 21.8% in AAV-injected hemispheres, a more than 4-fold increase in Ca²⁺-permeable AMPA receptor contribution, and GluA2 levels were reduced relative to GluA1.
- AAV upregulated H2-K and H2-D at 21 dpi and multiple cytokines/chemokines including IFN-γ, CD54, C5a, CXCL9, CXCL10, CXCL13, CCL2, and CCL5. The TLR9 antagonist ODN 2088 prevented AAV-induced dendritic loss and abolished the NASPM effect on sEPSC amplitude.
Methods
- Male C57BL/6J mice, 8–10 weeks old at injection, received unilateral stereotaxic injections of AAV8-hSyn-mCherry, AAV1-pCAG-FLEX-EGFP, vehicle, or sham surgery into S1, motor cortex, and/or cerebellum; tissues were collected at 4, 21, or 70 dpi.
- Dendritic morphology was assessed by DiOlistic labeling, blinded tracing, Sholl analysis, and Strahler order; cortical thickness and DAPI+ cell density were measured; synaptic transmission was assessed by whole-cell patch clamp for mEPSCs and sEPSCs with NASPM; immune readouts included RT-qPCR, western blotting, and cytokine arrays.
- Data were analyzed with Shapiro-Wilk normality tests, Grubb’s outlier tests, two-tailed unpaired t tests, and Kolmogorov-Smirnov tests for cumulative electrophysiology curves; dendritic data were often expressed as ipsilateral/contralateral ratios within animals.
Limitations
- Stated: it remains unknown whether AAV-induced dendritic loss occurs in non-human primates or humans, and species differences in TLR responses may limit translation; future studies are needed to define the individual roles of the many upregulated immune proteins.
- Stated: the authors cannot rule out that some analyzed neurons were transduced but expressed undetectably low mCherry, and it is likely many non-transduced neurons were included, suggesting the effects are unlikely to be cell autonomous.
- Evident: the study is limited to male C57BL/6J mice, specific AAV doses/routes/ages, and pharmacological TLR9 blockade rather than genetic TLR9 loss-of-function; dendritic sampling may underestimate loss because sectioning can truncate dendrites, as the authors note.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 84 cited sources checked · 0 supported · 0 flagged
- Findingown data
Dendritic loss is apparent 3 weeks after injection of experimentally relevant viral titers.
“Dendritic loss is apparent 3 weeks after injection of experimentally relevant viral titers”
Quote in the paperSubstantial claim - Findingown data
AAV-associated dendritic loss is accompanied by a decrease in the frequency of miniature excitatory postsynaptic currents.
“A decrease in the frequency and amplitude of miniature excitatory postsynaptic currents”
Quote in the paperSubstantial claim - Findingown data
AAV-mediated gene delivery reduces dendritic length and complexity in mouse somatosensory cortex.
“Here we find that an innate immune response to the AAV genome reduces dendritic length and complexity and disrupts synaptic transmission in mouse somatosensory cortex.”
Quote in the paperSubstantial claim - Findingown data
AAV-associated dendritic loss is accompanied by an increase in the proportion of GluA2-lacking, calcium-permeable AMPA receptors.
“an increase in the proportion of GluA2-lacking, calcium-permeable AMPA receptors”
Quote in the paperSubstantial claim - Findingown data
AAV-associated dendritic loss is accompanied by a decrease in the amplitude of miniature excitatory postsynaptic currents.
“A decrease in the frequency and amplitude of miniature excitatory postsynaptic currents”
Quote in the paperSubstantial claim
- Findingown data
AAV-associated dendritic loss is not restricted to a particular capsid serotype, transgene, promoter, or production facility.
“is not restricted to a particular capsid serotype, transgene, promoter, or production facility”
Quote in the paperSubstantial claim - Findingown data
Cortical thickness in AAV-injected hemispheres is slightly reduced from 4 to 21 dpi.
“cortical thickness in AAV-injected hemispheres is slightly reduced from 4 to 21 dpi”
Quote in the paperNot a substantial claim - Findingown data
Levels of caspase-3 are increased in the ipsilateral hemisphere at 21 dpi.
“Levels of caspase-3, a marker of apoptotic cell death, are also increased in the ipsilateral hemisphere at 21 dpi”
Quote in the paperSubstantial claim - Findingown data
NASPM blocked only a small fraction (5.1%) of the sEPSCs recorded at −70 mV in 11- to 14-week-old untreated controls.
“NASPM blocked only a small fraction (5.1%) of the sEPSCs recorded at −70 mV in 11- to 14-week-old untreated controls”
Quote in the paperSubstantial claim - Findingown data
Total dendritic length and Sholl intersections are significantly reduced in the ipsilateral hemisphere of AAV8-hSyn-mCherry-injected animals relative to both untreated control animals and vehicle-injected hemispheres.
“total dendritic length and Sholl intersections are significantly reduced in the ipsilateral hemisphere of AAV8-hSyn-mCherry-injected animals relative to both untreated control animals and vehicle-injected hemispheres”
Quote in the paperSubstantial claim - Findingown data
Loss of dendritic length and Sholl intersections are significantly reduced with the lower dose (2 × 109 vg) compared to 4 × 1010 vg.
“Loss of dendritic length and Sholl intersections are significantly reduced with this lower dose compared to 4 × 1010 vg”
Quote in the paperSubstantial claim - Findingown data
Loss of dendritic complexity in AAV-injected S1 is accompanied by a modest but persistent drop in cell density from 4 to 21 dpi that is still apparent at 70 dpi.
“Loss of dendritic complexity in AAV-injected S1 is accompanied by a modest but persistent drop in cell density from 4 to 21 dpi that is still apparent at 70 dpi”
Quote in the paperSubstantial claim - Findingown data
At 70 dpi, the non-injected contralateral hemisphere also shows significant loss of dendritic length and Sholl intersections compared to contralateral hemispheres at 4 and 21 dpi.
“at 70 dpi the non-injected contralateral hemisphere also shows significant loss of dendritic length and Sholl intersections compared to contralateral hemispheres at 4 and 21 dpi”
Quote in the paperSubstantial claim - Findingown data
Injecting AAV1-pCAG-FLEX-EGFP (PNI) into a single brain region (S1) produced changes in dendritic length and Sholl intersections comparable to those seen after injecting the same amount into three different brain regions.
“Injecting AAV1-pCAG-FLEX-EGFP (PNI) into a single brain region (S1) also produced changes in dendritic length and Sholl intersections comparable to those seen after injecting the same amount into three different brain regions”
Quote in the paperNot a substantial claim - Findingown data
In untreated controls, 29% of sampled pyramidal neurons in S1 reach SN4.
“In untreated controls, 29% of sampled pyramidal neurons in S1 reach SN4.”
Quote in the paperNot a substantial claim - Findingown data
Levels of H2-D protein inversely correlate with dendritic length across four conditions at 21 dpi.
“Levels of H2-D (and, to a lesser extent, H2-K) protein inversely correlate with dendritic length across four conditions (untreated, vehicle, AAV8-hSyn-mCherry, or AAV1-pCAG-FLEX-EGFP [UPenn]) at 21 dpi.”
Quote in the paperSubstantial claim - Findingown data
mEPSC amplitude is decreased in AAV-injected hemispheres compared to untreated controls.
“mEPSC amplitude is also decreased in AAV-injected hemispheres compared to untreated controls”
Quote in the paperSubstantial claim - Findingown data
Four days after administration of AAV1-pCAG-FLEX-EGFP (PNI) (1 × 1010 vg), a modest loss of Sholl intersections is already detectable near the neuronal soma in the ipsilateral hemisphere.
“Four days after administration AAV1-pCAG-FLEX-EGFP (PNI) (1 × 1010 vg) (Figure 2A), a modest loss of Sholl intersections is already detectable near the neuronal soma in the ipsilateral hemisphere”
Quote in the paperSubstantial claim - Findingown data
Increases in immune gene mRNA levels are restricted to the injected hemisphere.
“Like dendritic loss, increases in immune gene mRNA levels are restricted to the injected hemisphere”
Quote in the paperNot a substantial claim - Findingown data
After injection of the lower dose of AAV8-hSyn-mCherry (2 × 109 vg), 14% of pyramidal cells in the ipsilateral hemisphere reach SN4.
“After injection of the lower dose of AAV8-hSyn-mCherry (2 × 109 vg), which did not significantly affect total dendritic length or Sholl intersections (Figures 1C–1F), 14% of pyramidal cells in the ipsilateral hemisphere reach SN4”
Quote in the paperNot a substantial claim - Findingown data
Acutely blocking TLR9 preserves dendritic complexity in AAV-injected mice.
“acutely blocking TLR9 preserves dendritic complexity and AMPA receptor subunit composition in AAV-injected mice”
Quote in the paperSubstantial claim - Findingown data
The loss of Sholl intersections spreads throughout the dendritic arbor by 21 dpi.
“which spreads throughout the dendritic arbor by 21 dpi”
Quote in the paperNot a substantial claim - Findingown data
2 × 109 vg was not sufficient to drive strong mCherry expression in a cohort of animals with this combination of promoter, transgene, and route of administration.
“2 × 109 vg was not sufficient to drive strong mCherry expression in a cohort of animals with this combination of promoter, transgene, and route of administration”
Quote in the paperSubstantial claim - Findingown data
Recordings of sEPSCs showed a non-significant trend toward steeper rise slopes and shorter decay time constants in neurons from AAV-injected animals.
“recordings of spontaneous excitatory postsynaptic currents (sEPSCs) showed a non-significant trend toward steeper rise slopes and shorter decay time constants in neurons from AAV-injected animals”
Quote in the paperNot a substantial claim - Findingown data
Node loss is evenly distributed between the apical and basal dendritic compartments.
“node loss is evenly distributed between the apical and basal dendritic compartments”
Quote in the paperNot a substantial claim - Findingown data
In AAV8-hSyn-mCherry-injected hemispheres, mRNAs encoding H2-K, H2-D, and C3 are all significantly elevated relative to untreated controls at 4 dpi.
“In extracts from AAV8-hSyn-mCherry-injected hemispheres, mRNAs encoding H2-K, H2-D, and C3 are all significantly elevated relative to untreated controls at 4 dpi”
Quote in the paperSubstantial claim - Findingown data
Following unilateral injection of vehicle alone, dendritic length and Sholl intersections in injected hemispheres are indistinguishable from untreated controls.
“Following unilateral injection of vehicle alone, dendritic length and Sholl intersections in injected hemispheres are indistinguishable from untreated controls”
Quote in the paperSubstantial claim - Findingown data
Inter-event interval is increased in pyramidal cells from the AAV1-pCAG-FLEX-EGFP (UPenn)-injected hemisphere relative to untreated controls at 21 dpi.
“mEPSC frequency is reduced and inter-event interval is increased in pyramidal cells from the AAV1-pCAG-FLEX-EGFP (UPenn)-injected hemisphere relative to untreated (no surgical procedure) controls at 21 dpi”
Quote in the paperSubstantial claim - Findingown data
Vehicle injection modestly reduces levels of H2-K.
“vehicle injection modestly reduces levels of H2-K”
Quote in the paperNot a substantial claim - Findingown data
Following injection of AAV1-pCAG-FLEX-EGFP (UPenn), levels of GluA2 are significantly reduced relative to GluA1.
“Following injection of AAV1-pCAG-FLEX-EGFP (UPenn), levels of GluA2 are significantly reduced relative to GluA1”
Quote in the paperSubstantial claim - Findingown data
C3 is not increased by either AAV8-hSyn-mCherry or AAV1-pCAG-FLEX-EGFP (UPenn) at 21 dpi.
“while C3 is not increased by either virus at 21 dpi”
Quote in the paperSubstantial claim - Findingown data
Injection of 4 × 1010 viral genomes of AAV8-hSyn-mCherry into S1 drives robust mCherry expression.
“Injection of 4 × 1010 viral genomes (vg) of AAV8-hSyn-mCherry into S1 drives robust mCherry expression”
Quote in the paperSubstantial claim - Findingown data
At the lower dose (2 × 109 vg), dendritic length and Sholl intersections are indistinguishable from untreated controls.
“both measures are indistinguishable from those seen in untreated controls”
Quote in the paperSubstantial claim - Findingown data
mEPSC frequency is reduced in pyramidal cells from the AAV1-pCAG-FLEX-EGFP (UPenn)-injected hemisphere relative to untreated controls at 21 dpi.
“mEPSC frequency is reduced and inter-event interval is increased in pyramidal cells from the AAV1-pCAG-FLEX-EGFP (UPenn)-injected hemisphere relative to untreated (no surgical procedure) controls at 21 dpi”
Quote in the paperSubstantial claim - Findingown data
Acutely blocking TLR9 preserves AMPA receptor subunit composition in AAV-injected mice.
“acutely blocking TLR9 preserves dendritic complexity and AMPA receptor subunit composition in AAV-injected mice”
Quote in the paperSubstantial claim - Findingown data
AAV1-pCAG-FLEX-EGFP manufactured at either UPenn or Princeton Viral Vector Core caused nearly identical loss of dendritic length and Sholl intersections.
“AAV1-pCAG-FLEX-EGFP manufactured at either facility caused nearly identical loss of dendritic length and Sholl intersections”
Quote in the paperSubstantial claim - Findingown data
NASPM blocked 21.8% of the sEPSCs in AAV-injected hemispheres at the same age.
“NASPM blocked 21.8% of the sEPSCs in AAV-injected hemispheres at the same age”
Quote in the paperSubstantial claim - Findingown data
Sham surgery has no effect on the levels of H2-K, H2-D, C3, and Fyn immune proteins.
“Sham surgery has no effect on the levels of these immune proteins”
Quote in the paperSubstantial claim - Findingown data
The number of nodes in cells from injected ipsilateral hemispheres is significantly reduced relative to untreated controls after injection of either AAV8-hSyn-mCherry or AAV1-pCAG-FLEX-EGFP (UPenn).
“the number of nodes in cells from injected ipsilateral hemispheres, but not non-injected contralateral hemispheres, is significantly reduced relative to untreated controls”
Quote in the paperSubstantial claim - Findingown data
Injecting AAV1-pCAG-FLEX-EGFP (UPenn) in the presence of the TLR9 inhibitor ODN 2088 fully prevents dendritic loss.
“In striking contrast, injecting AAV1-pCAG-FLEX-EGFP (UPenn) in the presence of the TLR9 inhibitor ODN 2088 fully prevents dendritic loss.”
Quote in the paperSubstantial claim - Findingown data
Injection of AAV8-hSyn-mCherry into motor cortex and cerebellum (but not sham surgery) upregulates H2-K, C3, and Fyn protein levels in both areas at 21 dpi relative to untreated and vehicle controls.
“injection of AAV8-hSyn-mCherry into motor cortex and cerebellum (but not sham surgery) upregulates H2-K, C3, and Fyn protein levels in both areas at 21 dpi relative to untreated and vehicle controls”
Quote in the paperSubstantial claim - Findingnone given
Dendritic simplification is dose dependent.
“Dendritic simplification is dose dependent”
Quote in the paperNot a substantial claim - Findingown data
Systemic administration of an inactive analog of ODN 2088 or the TLR9 antagonist ODN 2088 does not alter dendritic length or complexity in cortical pyramidal cells of non-injected contralateral S1 in AAV-injected animals.
“In AAV-injected animals, systemic administration of either an inactive analog of ODN 2088 or the TLR9 antagonist ODN 2088 does not alter dendritic length or complexity in cortical pyramidal cells of non-injected contralateral S1 (not shown), suggesting that these oligonucleotides alone do not alter dendritic arbors.”
Quote in the paperSubstantial claim - Findingown data
NASPM does not significantly change sEPSC amplitude in untreated controls.
“(F–H) NASPM does not significantly change sEPSC amplitude in untreated controls”
Quote in the paperSubstantial claim - Findingown data
In animals treated with TLR9 inhibitor, total dendritic length and Sholl intersections in AAV-injected hemispheres are significantly increased relative to AAV-injected hemispheres in the presence or absence of ODN CTL at 21 dpi.
“In animals treated with the TLR9 inhibitor, total dendritic length and Sholl intersections in AAV-injected hemispheres are significantly increased relative to AAV-injected hemispheres in the presence or absence of ODN CTL”
- Also stated in: § Dendritic morphology and synaptic transmission are preserved by limiting detection of the AAV genome by TLR9 · plain
“(B and C) Total dendritic length and Sholl intersections for AAV1 + ODN 2088 are significantly higher than for AAV1 + ODN CTL”
Quote in the paperSubstantial claim - Also stated in: § Dendritic morphology and synaptic transmission are preserved by limiting detection of the AAV genome by TLR9 · plain
- Findingown data
Treatment with TLR9 inhibitor ODN 2088 abolishes the effect of NASPM on sEPSC amplitude in AAV-injected animals.
“Treatment with the TLR9 inhibitor ODN 2088 abolishes the effect of NASPM on sEPSC amplitude in AAV-injected animals.”
Quote in the paperSubstantial claim - Findingown data
Persistent upregulation of multiple immune proteins that act downstream of TLR9, including CD54, CCL2, CCL5, IFN-γ, CXCL13, and CXCL10, is seen in injected S1.
“Finally, we see persistent upregulation of multiple immune proteins that act downstream of TLR9, including CD54, CCL2, CCL5, IFN-γ, CXCL13, and CXCL10, in injected S1.”
Quote in the paperSubstantial claim - Findingown data
AAV-induced upregulation of several immune proteins that act downstream of TLR9 and can regulate dendritic complexity, including H2-K, H2-D, and C3, is seen.
“We see AAV-induced upregulation of several immune proteins that act downstream of TLR9 and can regulate dendritic complexity, including H2-K, H2-D, and C3.”
Quote in the paperSubstantial claim - Findingnone given
Dendritic simplification is not restricted to a specific AAV capsid serotype, promoter, preparation facility, or encoded transgene.
“and is not restricted to a specific AAV capsid serotype, promoter, preparation facility, or encoded transgene.”
Quote in the paperSubstantial claim - Findingown data
After injection of AAV1-pCAG-FLEX-EGFP (UPenn), multiple cytokines and chemokines are upregulated in injected S1 relative to untreated controls, including IFN-γ, CD54 (sICAM-1), complement component C5a, CXCL9 (MIG), CXCL10 (IP-10), CXCL13 (BLC), CCL2 (JE), and CCL5 (RANTES).
“After injection of AAV1-pCAG-FLEX-EGFP (UPenn), multiple cytokines and chemokines are upregulated in injected S1 relative to untreated controls, including IFN-γ, CD54 (sICAM-1), complement component C5a, CXCL9 (MIG), CXCL10 (IP-10), CXCL13 (BLC), CCL2 (JE), and CCL5 (RANTES)”
Quote in the paperSubstantial claim - Findingown data
NASPM significantly decreases sEPSC amplitude in cells from AAV1 injected hemispheres.
“but significantly decreases sEPSC amplitude in cells from AAV1 injected hemispheres.”
Quote in the paperSubstantial claim - Findingown data
Dendritic loss is accompanied by an increase in the relative contribution of Ca2+-permeable AMPA receptors.
“and an increase in the relative contribution of Ca2+-permeable AMPA receptors.”
Quote in the paperNot a substantial claim - Findingown data
C3 and Fyn levels do not correlate with dendritic length at 21 dpi.
“In contrast, C3 and Fyn levels do not correlate with dendritic length at this time point”
Quote in the paperSubstantial claim - Findingown data
The increase in response to NASPM is prevented in AAV-treated animals that received the TLR9 blocker ODN 2088.
“However, this increase in response to NASPM is prevented in AAV-treated animals that received the TLR9 blocker ODN 2088 (Figures 5F–5H).”
Quote in the paperSubstantial claim - Findingown data
Levels of H2-K protein inversely correlate with dendritic length across four conditions at 21 dpi, to a lesser extent than H2-D.
“Levels of H2-D (and, to a lesser extent, H2-K) protein inversely correlate with dendritic length across four conditions (untreated, vehicle, AAV8-hSyn-mCherry, or AAV1-pCAG-FLEX-EGFP [UPenn]) at 21 dpi.”
Quote in the paperSubstantial claim - Findingown data
Dendritic loss in pyramidal neurons of somatosensory cortex is apparent at 21 dpi.
“Dendritic loss in pyramidal neurons of somatosensory cortex is apparent at 21 dpi”
Quote in the paperSubstantial claim - Findingown data
The fraction of sEPSCs inhibited by NASPM is increased in AAV-treated animals.
“and increased in AAV-treated animals.”
Quote in the paperSubstantial claim - Findingown data
The fraction of sEPSCs inhibited by NASPM, representing calcium-permeable AMPA receptors that lack the GluA2 subunit, is small in control animals.
“the fraction of the sEPSCs that is inhibited by NASPM, representing calcium-permeable AMPA receptors that lack the GluA2 subunit, is small in control animals”
Quote in the paperNot a substantial claim - Findingown data
mCherry was not associated with changes in the levels of H2-K, H2-D, Fyn, or C3 in non-injected brain regions.
“mCherry was not associated with changes in the levels of H2-K, H2-D, Fyn, or C3 in either region”
Quote in the paperSubstantial claim - Findingown data
Continued upregulation of H2-K and H2-D proteins is seen 3 weeks after injection of AAV in somatosensory cortex, motor cortex, and cerebellum.
“In addition to this rapid response, we see continued upregulation of H2-K and H2-D proteins 3 weeks after injection of AAV in somatosensory cortex, motor cortex, and cerebellum.”
Quote in the paperNot a substantial claim - Findingown data
Injection of AAV1-pCAG-FLEX-EGFP (UPenn) in the presence of control oligonucleotide ODN CTL reduces dendritic length and complexity at 21 dpi in ipsilateral S1 in a manner that closely resembles changes caused by the virus alone.
“Injection of AAV1-pCAG-FLEX-EGFP (UPenn) in the presence of control oligonucleotide (ODN CTL) still reduces dendritic length and complexity at 21 dpi in ipsilateral S1 in a manner that closely resembles changes caused by the virus alone.”
Quote in the paperSubstantial claim - Findingown data
AAV1-pCAG-FLEX-EGFP causes severe deficits in the absence of detectable transgene expression.
“First, AAV1-pCAG-FLEX-EGFP causes severe deficits in the absence of detectable transgene expression.”
Quote in the paperSubstantial claim - Findingown data
Dendritic loss is accompanied by a decrease in the frequency and amplitude of mEPSCs.
“and is accompanied by a decrease in the frequency and amplitude of mEPSCs”
Quote in the paperSubstantial claim - Findingown data
Dendritic simplification does not require transgene expression.
“does not require transgene expression”
- Also stated in: § Discussion · plain
“transgene expression is neither necessary nor sufficient for AAV-associated dendritic loss.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Findingown data
Disrupted neural structure and function in AAV-injected animals is associated with rapid and persistent upregulation of multiple downstream targets of TLR9.
“Disrupted neural structure and function in AAV-injected animals is associated with rapid and persistent upregulation of multiple downstream targets of TLR9”
Quote in the paperSubstantial claim - Findingown data
In animals treated with TLR9 inhibitor, total dendritic length and Sholl intersections in AAV-injected hemispheres are indistinguishable from untreated controls at 21 dpi.
“and are indistinguishable from untreated controls at 21 dpi (Figures 5A–5E).”
- Also stated in: § Dendritic morphology and synaptic transmission are preserved by limiting detection of the AAV genome by TLR9 · plain
“and are indistinguishable from untreated controls.”
Quote in the paperSubstantial claim - Also stated in: § Dendritic morphology and synaptic transmission are preserved by limiting detection of the AAV genome by TLR9 · plain
- Findingown data
AAV-induced dendritic simplification can be avoided by systemic administration of a TLR9 antagonist, ODN 2088.
“Finally, we show that AAV-induced dendritic simplification can be avoided by systemic administration of a TLR9 antagonist, ODN 2088.”
Quote in the paperSubstantial claim - Findingown data
Reducing the dose of AAV can largely prevent dendritic simplification.
“We find that reducing the dose of AAV can largely prevent dendritic simplification.”
Quote in the paperSubstantial claim - Findingown data
Protection is conferred by diluting the virus.
“First, the protection conferred by diluting the virus suggests that lowering the number of viral genomes administered is the most straightforward strategy to reduce the negative impacts of AAV on dendritic morphology.”
Quote in the paperSubstantial claim - Findingown data
Dendritic length, nodes, and Sholl intersections for cells in the contralateral hemisphere at 21 dpi were indistinguishable from untreated controls.
“Dendritic length, nodes, and Sholl intersections for cells in the contralateral hemisphere at 21 dpi were indistinguishable from untreated controls”
Quote in the paperSubstantial claim - Interpretationown data
AAV-associated dendritic loss cannot be explained by responses to surgery or transgene expression.
“cannot be explained by responses to surgery or transgene expression”
Quote in the paperSubstantial claim - Premisecitation
CNS-directed AAV delivery has been associated with an increase in inflammatory mediators, including neutralizing antibodies, circulating CD45+ leukocytes, natural killer cells, and CD8+ and CD4+ T cells.
“CNS-directed AAV delivery has been associated with an increase in inflammatory mediators, including neutralizing antibodies, circulating CD45+ leukocytes, natural killer cells, and CD8+ and CD4+ T cells.13,14,15,16,17,18,19”
Quote in the paperSubstantial claim0 of 7 sources checked- cites [13] Bainbridge, 2008, Effect of gene therapy on visual function in Leber’s congenital amaurosis, N. Engl. J. Med. source
Not checked in the free run.
- cites [14] Chandler, 2021, Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
- cites [15] Ciesielska, 2013, Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses, Mol. Ther. source
Not checked in the free run.
- cites [16] Sondhi, 2020, Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2, Sci. Transl. Med. source
Not checked in the free run.
- cites [17] Tardieu, 2017, Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial, Lancet Neurol. source
Not checked in the free run.
- cites [18] Timmers, 2020, Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid, Hum. Gene Ther. source
Not checked in the free run.
- cites [19] Whitehead, 2021, Humoral immune responses to AAV gene therapy in the ocular compartment. Biol. Rev, n/a
Not checked in the free run.
- Interpretationown data
AAV administration causes a drop in branching depth that accompanies loss of dendritic length and complexity.
“These results reveal a drop in branching depth after administration of AAV that accompanies loss of dendritic length and complexity.”
Quote in the paperSubstantial claim - Interpretationown data
AAV-mediated gene delivery causes rapid and persistent dendritic loss that begins within days and progresses within the first few weeks after injection.
“AAV-mediated gene delivery causes rapid and persistent dendritic loss that begins within days and progresses within the first few weeks after injection”
Quote in the paperSubstantial claim - Premisecitation
Many immune proteins have non-immune roles in the healthy nervous system, where they are required for normal neuronal development, dendritic morphology, and synaptic transmission.
“many immune proteins have non-immune roles in the healthy nervous system, where they are required for normal neuronal development, dendritic morphology, and synaptic transmission.”
Quote in the paperSubstantial claim0 of 6 sources checked- cites [20] Datwani, 2009, Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity, Neuron source
Not checked in the free run.
- cites [21] Huh, 2000, Functional requirement for class I MHC in CNS development and plasticity, Science source
Not checked in the free run.
- cites [22] Lee, 2014, Synapse elimination and learning rules co-regulated by MHC class I H2-D b, Nature source
Not checked in the free run.
- cites [23] Schafer, 2012, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner, Neuron source
Not checked in the free run.
- cites [24] Stevens, 2007, The classical complement cascade mediates CNS synapse elimination, Cell source
Not checked in the free run.
- cites [25] Yilmaz, 2021, Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice, Nat. Neurosci. source
Not checked in the free run.
- Interpretationreasoning
Some aspect of surgical delivery of AAV to the brain is implicated in more widespread neuropathology at 70 dpi.
“implicating some aspect of surgical delivery of AAV to the brain in more widespread neuropathology at 70 dpi”
Quote in the paperSubstantial claim - Interpretationown data
The reduction in GluA2 relative to GluA1 is consistent with a shift toward more GluA2-lacking, Ca2+-permeable AMPA receptors.
“consistent with a shift toward more GluA2-lacking, Ca2+-permeable AMPA receptors”
Quote in the paperSubstantial claim - Interpretationown data
AAV-mediated gene delivery rapidly upregulates the expression of multiple immune genes that can regulate dendritic complexity and synaptic transmission.
“AAV-mediated gene delivery rapidly upregulates the expression of multiple immune genes that can regulate dendritic complexity and synaptic transmission”
Quote in the paperSubstantial claim - Interpretationown data
Dendritic loss does not require detectable transgene expression.
“dendritic loss does not require detectable transgene expression”
Quote in the paperSubstantial claim - Interpretationown data
Dendritic loss is not restricted to a specific encoded transgene.
“demonstrating that dendritic loss is not restricted to a specific encoded transgene”
Quote in the paperSubstantial claim - Interpretationown data
AAV-mediated gene delivery is associated with loss of entire branches throughout the dendritic arbor in the injected hemisphere.
“AAV-mediated gene delivery is associated with loss of entire branches throughout the dendritic arbor in the injected hemisphere”
Quote in the paperSubstantial claim - Interpretationown data
The eventual equalization of dendritic arbors in ipsilateral and contralateral hemispheres by 70 dpi does not represent dendritic recovery but rather reflects a similar loss of dendritic complexity in both injected and non-injected hemispheres at this later time point.
“the eventual equalization of dendritic arbors in ipsilateral and contralateral hemispheres by 70 dpi does not represent dendritic recovery but rather reflects a similar loss of dendritic complexity in both injected and non-injected hemispheres at this later time point”
Quote in the paperSubstantial claim - Interpretationown data
Dendritic loss is caused by AAVs with diverse features.
“demonstrating that dendritic loss is caused by AAVs with diverse features”
Quote in the paperSubstantial claim - Interpretationown data
There is a more than 4-fold increase in the fraction of the current carried by Ca2+-permeable AMPA receptors after AAV injection.
“indicating a more than 4-fold increase in the fraction of the current carried by Ca2+-permeable AMPA receptors after AAV injection”
Quote in the paperSubstantial claim - Premisecitation
The TLR9 gene is expressed by microglia, astrocytes, and neurons in the CNS.
“The TLR9 gene is expressed by microglia, astrocytes, and neurons in the CNS”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [49] Doi, 2009, Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid β Neurotoxicity in in Vitro and in Vivo Models of Alzheimer’s Disease, Am. J. Pathol. source
Not checked in the free run.
- cites [50] Kaul, 2012, Expression of Toll-Like Receptors in the Developing Brain, PLOS ONE source
Not checked in the free run.
- cites [51] Li, 2020, Astroglial TLR9 antagonism promotes chemotaxis and alternative activation of macrophages via modulation of astrocyte-derived signals: implications for spinal cord injury, J. Neuroinflammation source
Not checked in the free run.
- Interpretationown data
An innate immune response to AAV's genome significantly impacts circuit structure and function.
“These results reveal that an innate immune response to AAV’s genome significantly impacts circuit structure and function”
Quote in the paperSubstantial claim - Interpretationown data
AAV administration in the CNS causes increases in multiple innate and adaptive immune molecules that are consistent with AAV-induced activation of TLR9.
“cytokine arrays, RT-qPCR, and western blots demonstrate that AAV administration in the CNS causes increases in multiple innate and adaptive immune molecules that are consistent with AAV-induced activation of TLR9”
Quote in the paperSubstantial claim - Interpretationreasoning
Dendritic loss is linked to the presence of AAV genomes, not transgene products.
“The fact that dendritic loss is linked to the presence of AAV genomes, not transgene products”
Quote in the paperSubstantial claim - Premisecitation
All of the AAV-induced cytokines and chemokines can be upregulated by activation of TLR9 in the periphery using synthetic CpG-rich oligonucleotides.
“all of the AAV-induced cytokines and chemokines can be upregulated by activation of TLR9 in the periphery using synthetic CpG-rich oligonucleotides.8,9,10,11,12,52,53,54,55,56,57,58”
Quote in the paperSubstantial claim0 of 10 sources checked- cites [8] Ashley, 2019, TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy, Cell. Immunol. source
Not checked in the free run.
- cites [9] Martino, 2011, The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9–dependent innate immune responses in the liver, Blood source
Not checked in the free run.
- cites [10] Rogers, 2011, Innate Immune Responses to AAV Vectors, Front. Microbiol. source
Not checked in the free run.
- cites [11] Rogers, 2017, Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells, Blood source
Not checked in the free run.
- cites [12] Shirley, 2020, Immune Responses to Viral Gene Therapy Vectors, Mol. Ther. source
Not checked in the free run.
- cites [52] Hemmi, 2000, A Toll-like receptor recognizes bacterial DNA, Nature source
Not checked in the free run.
- cites [53] Kuchtey, 2005, Enhancement of Dendritic Cell Antigen Cross-Presentation by CpG DNA Involves Type I IFN and Stabilization of Class I MHC mRNA, J. Immunol. source
Not checked in the free run.
- cites [54] Mangsbo, 2009, Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects, J. Immunol. source
Not checked in the free run.
- cites [55] Pasch, 2000, Synthesis of Complement Components C3 and Factor B in Human Keratinocytes is Differentially Regulated by Cytokines, J. Invest. Dermatol. source
Not checked in the free run.
- cites [56] Butchi, 2010, Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia, Glia source
Not checked in the free run.
- Interpretationown data
Dendritic loss induced by AAV-mediated gene delivery is associated with rapid and persistent upregulation of multiple immune molecules with known roles in neuronal homeostasis.
“dendritic loss induced by AAV-mediated gene delivery is associated with rapid and persistent upregulation of multiple immune molecules with known roles in neuronal homeostasis”
Quote in the paperSubstantial claim - Interpretationown data
AAV's genome is rapidly detected by TLR9 in the CNS.
“Together, these results suggest that AAV’s genome is rapidly detected by TLR9 in the CNS”
Quote in the paperSubstantial claim - Interpretationown data
Upregulation of immune gene expression after AAV transduction is associated with structural and functional changes in pyramidal neurons.
“Overall, our studies show that upregulation of immune gene expression after AAV transduction is associated with structural and functional changes in pyramidal neurons”
Quote in the paperSubstantial claim - Interpretationreasoning
Targeting individual upregulated immune proteins is unlikely to fully prevent AAV-induced dendritic changes.
“targeting individual upregulated immune proteins is unlikely to fully prevent AAV-induced dendritic changes”
Quote in the paperSubstantial claim - Interpretationown data
Immunodetection of AAV's genome by TLR9 is the triggering event.
“and that immunodetection of AAV’s genome by TLR9 is the triggering event.”
Quote in the paperSubstantial claim - Premisecitation
TLR9 activation is an early and transient event in the immune response to the AAV genome.
“TLR9 activation is an early and transient event in the immune response to the AAV genome.9”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [9] Martino, 2011, The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9–dependent innate immune responses in the liver, Blood source
Not checked in the free run.
- Premisecitation
Responses to unmethylated CpG DNA have been detected in CNS cells.
“responses to unmethylated CpG DNA have been detected in CNS cells.49,50,51”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [49] Doi, 2009, Microglia Activated with the Toll-Like Receptor 9 Ligand CpG Attenuate Oligomeric Amyloid β Neurotoxicity in in Vitro and in Vivo Models of Alzheimer’s Disease, Am. J. Pathol. source
Not checked in the free run.
- cites [50] Kaul, 2012, Expression of Toll-Like Receptors in the Developing Brain, PLOS ONE source
Not checked in the free run.
- cites [51] Li, 2020, Astroglial TLR9 antagonism promotes chemotaxis and alternative activation of macrophages via modulation of astrocyte-derived signals: implications for spinal cord injury, J. Neuroinflammation source
Not checked in the free run.
- Interpretationreasoning
AAV genomes appear to be the triggering signal for dendritic loss and synaptic disruption.
“which appear to be the triggering signal for dendritic loss and synaptic disruption.”
Quote in the paperSubstantial claim - Interpretationown data
Transient administration of a TLR9 inhibitor around the time of injection can protect against AAV-induced changes in dendritic morphology and excitatory synaptic transmission.
“and that transient administration of a TLR9 inhibitor around the time of injection can protect against AAV-induced changes in dendritic morphology and excitatory synaptic transmission.”
Quote in the paperSubstantial claim - Study design and conductreasoning
Reported values could be an underestimate of the extent of the dendritic loss caused by AAV.
“Thus, the reported values could be an underestimate of the extent of the dendritic loss caused by AAV.”
Quote in the paperNot a substantial claim - Interpretationreasoning
It is likely that many non-transduced neurons were included in the analysis.
“it is likely that many non-transduced neurons were included in the analysis”
Quote in the paperSubstantial claim - Interpretationreasoning
Common contaminants, such as endotoxin, are unlikely to cause AAV-associated changes that are prevented by TLR9 blockers, because these contaminants are detected by other members of the TLR family.
“A variety of common contaminants, such as endotoxin, are unlikely to cause AAV-associated changes that are prevented by TLR9 blockers, because these contaminants are detected by other members of the TLR family.”
Quote in the paperSubstantial claim - Study design and conductown data
Sampling of a heterogeneous cell population and truncation of dendrites as an unavoidable consequence of tissue sectioning cannot explain the differences seen between AAV-injected hemispheres and untreated and vehicle-injected animals, or non-injected contralateral hemispheres in the same animal.
“However, these factors cannot explain the differences we see between AAV-injected hemispheres and untreated and vehicle-injected animals, or non-injected contralateral hemispheres in the same animal.”
Quote in the paperSubstantial claim - Premisecitation
Innate immune pathways in apes are markedly more sensitive than those in African and Asian monkeys.
“One clue to the poor predictability of animal models for human innate immune responses may lie in the finding that innate immune pathways in apes are markedly more sensitive than those in African and Asian monkeys.85”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [85] Hawash, 2021, Primate innate immune responses to bacterial and viral pathogens reveals an evolutionary trade-off between strength and specificity, Proc. Natl. Acad. Sci. USA source
Not checked in the free run.
- Interpretationreasoning
Most if not all AAV genomes have the potential to disrupt circuit structure and function.
“Since unmethylated CpGs are a core feature of the AAV genome, the current results suggest that most if not all AAV genomes have the potential to disrupt circuit structure and function.”
Quote in the paperSubstantial claim- Rests on an assumption: Unmethylated CpG motifs are a core feature of the AAV genome.
- Interpretationown data
The neuronal effects of AAV seen are TLR9 dependent.
“The neuronal effects of AAV that we see are TLR9 dependent”
Quote in the paperSubstantial claim - Interpretationown data
AAV-induced dendritic loss affects multiple cell types in S1.
“The presence of significant dendritic loss throughout the broad cell population sampled (Figure S1H) further suggests that AAV-induced dendritic loss affects multiple cell types in S1.”
Quote in the paperNot a substantial claim - Premisecitation
The AAVs used here are nearly identical in their predicted ability to activate TLR9, using a metric (RF3) that takes into account several known TLR9 agonist and antagonist motifs.
“Indeed, while the AAVs used here differ in many ways, they are nearly identical in their predicted ability to activate TLR9, using a metric (RF3) that takes into account several known TLR9 agonist and antagonist motifs.86”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [86] Wright, 2020, Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll, Mol. Ther. source
Not checked in the free run.
- Interpretationown data
AAV8-hSyn-mCherry and AAV1-pCAG-FLEX-EGFP do not alter the morphology of pyramidal cells within the contralateral hemisphere at this age.
“indicating that AAV8-hSyn-mCherry and AAV1-pCAG-FLEX-EGFP do not alter the morphology of pyramidal cells within the contralateral hemisphere at this age (Figure S1).”
Quote in the paperSubstantial claim - Study design and conductown data
The similarity of dendrites in untreated animals and in the contralateral hemisphere of AAV-injected animals suggests that consistent morphology can be obtained across animals despite sampling a heterogeneous cell population and small differences in the plane of section for each brain.
“The similarity of dendrites in untreated animals and in the contralateral hemisphere of AAV-injected animals suggests that consistent morphology can be obtained across animals despite sampling a heterogeneous cell population and small differences in the plane of section for each brain.”
Quote in the paperNot a substantial claim - Interpretationown data
The effects of AAV on dendritic morphology and synaptic transmission are unlikely to be cell autonomous.
“suggesting that the effects of AAV on dendritic morphology and synaptic transmission are unlikely to be cell autonomous.”
Quote in the paperSubstantial claim
- The quote only partly states this claim. 1
- May combine two claims. 40
- Classified as probably not a substantial claim. 39
The quote only partly states this claim.
Findingown dataAAV-mediated gene delivery disrupts synaptic transmission in mouse somatosensory cortex.
“AAV1-pCAG-FLEX-EGFP disrupts synaptic transmission”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBy 70 dpi, dendritic length and Sholl intersections between ipsilateral and contralateral hemispheres are indistinguishable.
“By 70 dpi, dendritic length and Sholl intersections between ipsilateral and contralateral hemispheres are indistinguishable”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn the non-injected contralateral hemispheres, total dendritic length and Sholl intersections are indistinguishable from untreated controls.
“In the non-injected contralateral hemispheres, total dendritic length and Sholl intersections are indistinguishable from untreated controls”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBoth AAV8-hSyn-mCherry and AAV1-pCAG-FLEX-EGFP (UPenn) significantly upregulate H2-K and H2-D relative to untreated and vehicle controls at 21 dpi.
“both AAV8-hSyn-mCherry (1.2 × 1011 vg) and AAV1-pCAG-FLEX-EGFP (UPenn) (4.2 × 109 vg) significantly upregulate H2-K and H2-D relative to untreated and vehicle controls at 21 dpi”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAAV1-pCAG-FLEX-EGFP still causes a significant reduction in total dendritic length and Sholl intersections, closely matching what is seen after AAV8-hSyn-mCherry.
“AAV1-pCAG-FLEX-EGFP still causes a significant reduction in total dendritic length and Sholl intersections, closely matching what is seen after AAV8-hSyn-mCherry”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataOnly 4% of cells from the injected ipsilateral hemisphere reach SN4 after AAV8-hSyn-mCherry, and 7% after AAV1-pCAG-FLEX-EGFP (UPenn).
“only 4% (after AAV8-hSyn-mCherry) or 7% (after AAV1-pCAG-FLEX-EGFP (UPenn)) reach SN4”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataUntreated animals at 18-20 weeks old showed no significant loss of dendritic length or Sholl intersections relative to younger adults.
“Untreated animals at 18–20 weeks old showed no significant loss of dendritic length or Sholl intersections relative to younger adults”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataFyn is persistently upregulated by AAV8-hSyn-mCherry but not AAV1-pCAG-FLEX-EGFP (UPenn) at 21 dpi.
“Fyn is persistently upregulated by AAV8-hSyn-mCherry but not AAV1-pCAG-FLEX-EGFP (UPenn)”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataDendritic complexity in contralateral S1 at 21 dpi is indistinguishable from untreated controls, despite the presence of mCherry that is trafficked from the injected hemisphere.
“Third, dendritic complexity in contralateral S1 at 21 dpi is indistinguishable from untreated controls, despite the presence of mCherry that is trafficked from the injected hemisphere.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBlocking immunodetection of the AAV genome via TLR9 preserves dendritic arbors and maintains normal AMPA receptor responses in AAV-injected animals.
“and blocking immunodetection of the AAV genome via TLR9 preserves dendritic arbors and maintains normal AMPA receptor responses in AAV-injected animals.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataIn AAV8-hSyn-mCherry-injected animals, cells that expressed readily detectable mCherry were not traced, but significant dendritic loss was still observed.
“Second, in AAV8-hSyn-mCherry-injected animals, cells that expressed readily detectable mCherry were not traced (see materials and methods), but significant dendritic loss was still observed.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAn immune response to the AAV genome significantly reduces dendritic complexity and disrupts synaptic transmission in adult rodent cortex.
“Here, we show that an immune response to the AAV genome significantly reduces dendritic complexity and disrupts synaptic transmission in adult rodent cortex.”
- Also stated in: § Discussion · plain
“These results reveal that an innate immune response to AAV’s genome significantly impacts circuit structure and function”
Quote in the paperSubstantial claim- Also stated in: § Discussion · plain
May combine two claims.
Findingown dataTransgene expression is seen in fibers in contralateral S1, which does not show upregulation of immune genes or changes in dendritic structure at 21 dpi.
“We see transgene expression in fibers in contralateral S1, which does not show upregulation of immune genes or changes in dendritic structure at 21 dpi”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataThere was no detectable mCherry mRNA in untreated or sham surgery samples.
“There was no detectable mCherry mRNA in untreated or sham surgery samples, so the lowest possible CT values (50) were assigned to these samples.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationH2-K and H2-D limit the levels of Ca2+-permeable AMPA receptors in the lateral geniculate nucleus.
“limit the levels of Ca2+-permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the lateral geniculate nucleus.21,22,26,27,28,29”
Quote in the paperNot a substantial claim0 of 6 sources checked- cites [21] Huh, 2000, Functional requirement for class I MHC in CNS development and plasticity, Science source
Not checked in the free run.
- cites [22] Lee, 2014, Synapse elimination and learning rules co-regulated by MHC class I H2-D b, Nature source
Not checked in the free run.
- cites [26] Dixon-Salazar, 2014, MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling, J. Neurosci. source
Not checked in the free run.
- cites [27] Glynn, 2011, MHCI negatively regulates synapse density during the establishment of cortical connections, Nat. Neurosci. source
Not checked in the free run.
- cites [28] Hu, 2020, MiR34a Regulates Neuronal MHC Class I Molecules and Promotes Primary Hippocampal Neuron Dendritic Growth and Branching, Front. Cell. Neurosci. source
Not checked in the free run.
- cites [29] Shen, 2019, MHC Class I Molecules and PirB Shape Neuronal Morphology by Affecting the Dendritic Arborization of Cortical Neurons, Neurochem. Res. source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
PremisecitationH2-K and H2-D negatively regulate dendritic complexity and the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) in hippocampal and cortical neurons.
“H2-K and H2-D also negatively regulate dendritic complexity and the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) in hippocampal and cortical neurons”
Quote in the paperSubstantial claim0 of 6 sources checked- cites [21] Huh, 2000, Functional requirement for class I MHC in CNS development and plasticity, Science source
Not checked in the free run.
- cites [22] Lee, 2014, Synapse elimination and learning rules co-regulated by MHC class I H2-D b, Nature source
Not checked in the free run.
- cites [26] Dixon-Salazar, 2014, MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling, J. Neurosci. source
Not checked in the free run.
- cites [27] Glynn, 2011, MHCI negatively regulates synapse density during the establishment of cortical connections, Nat. Neurosci. source
Not checked in the free run.
- cites [28] Hu, 2020, MiR34a Regulates Neuronal MHC Class I Molecules and Promotes Primary Hippocampal Neuron Dendritic Growth and Branching, Front. Cell. Neurosci. source
Not checked in the free run.
- cites [29] Shen, 2019, MHC Class I Molecules and PirB Shape Neuronal Morphology by Affecting the Dendritic Arborization of Cortical Neurons, Neurochem. Res. source
Not checked in the free run.
May combine two claims.
Interpretationown dataDendritic simplification is not caused by surgery or vehicle injection but is specifically associated with the presence of AAV.
“Dendritic loss in AAV-injected but not vehicle-injected animals suggests that dendritic simplification is not caused by surgery or vehicle injection but rather is specifically associated with the presence of AAV.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn the periphery, AAV-mediated gene delivery can elicit humoral, cellular, and innate immune responses to features including the viral capsid, expressed transgene, and impurities from the viral preparation.
“In the periphery, AAV-mediated gene delivery can elicit humoral, cellular, and innate immune responses to features including the viral capsid, expressed transgene, and impurities from the viral preparation,6,7”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [6] Ertl, 2022, Immunogenicity and toxicity of AAV gene therapy, Front. Immunol. source
Not checked in the free run.
- cites [7] Wright, 2014, Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment, Biomedicines source
Not checked in the free run.
May combine two claims.
Interpretationown dataAAV-mediated gene delivery causes a decrease in synapse number that parallels the loss of dendritic length and complexity and disrupts synaptic transmission at remaining synapses.
“AAV-mediated gene delivery causes a decrease in synapse number that parallels the loss of dendritic length and complexity and disrupts synaptic transmission at remaining synapses”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationProteins of the complement cascade (including C1q, C3, and C4) and members of MHCI (including H2-K and H2-D) contribute to synapse elimination in the developing visual system.
“proteins of the complement cascade (including C1q, C3, and C4) and members of MHCI (including H2-K and H2-D) contribute to synapse elimination in the developing visual system.20,21,22,23,24,25”
Quote in the paperSubstantial claim0 of 6 sources checked- cites [20] Datwani, 2009, Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity, Neuron source
Not checked in the free run.
- cites [21] Huh, 2000, Functional requirement for class I MHC in CNS development and plasticity, Science source
Not checked in the free run.
- cites [22] Lee, 2014, Synapse elimination and learning rules co-regulated by MHC class I H2-D b, Nature source
Not checked in the free run.
- cites [23] Schafer, 2012, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner, Neuron source
Not checked in the free run.
- cites [24] Stevens, 2007, The classical complement cascade mediates CNS synapse elimination, Cell source
Not checked in the free run.
- cites [25] Yilmaz, 2021, Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice, Nat. Neurosci. source
Not checked in the free run.
May combine two claims.
InterpretationreasoningThe smaller amplitude of mEPSCs recorded in neurons from AAV-injected animals is unlikely to be caused by smaller dendritic arbors but could occur if there was a change in AMPA receptor subunit composition.
“The smaller amplitude of mEPSCs recorded in neurons from AAV-injected animals are unlikely to be caused by smaller dendritic arbors but could occur if there was a change in AMPA receptor subunit composition.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataDendritic loss is not specific to a particular capsid serotype, promoter, encoded transgene, or production facility but is triggered by AAV-based gene delivery systems that differ in all these parameters.
“dendritic loss does not require detectable transgene expression and is not specific to a particular capsid serotype, promoter, encoded transgene, or production facility but is triggered by AAV-based gene delivery systems that differ in all these parameters.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataAAV-mediated gene delivery can cause modest cortical thinning and cell death in mouse cortex.
“AAV-mediated gene delivery can cause modest cortical thinning and cell death in mouse cortex”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationITR-driven toxicity does not require Sting, a TLR9-independent pathway for detecting foreign DNA.
“This ITR-driven toxicity does not require Sting, a TLR9-independent pathway for detecting foreign DNA.63”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [63] Johnston, 2021, AAV ablates neurogenesis in the adult murine hippocampus, eLife source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataNo-primary controls show lack of non-specific labeling.
“No-primary controls show lack of non-specific labeling”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationAAV-mediated gene delivery into the CNS of pigs or non-human primates causes dorsal root ganglion toxicity that is alleviated by reducing or deleting transgene expression.
“For example, AAV-mediated gene delivery into the CNS of pigs or non-human primates causes dorsal root ganglion toxicity that is alleviated by reducing or deleting transgene expression.38,39,66”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [38] Hordeaux, 2018, Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
- cites [39] Hordeaux, 2020, MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates, Sci. Transl. Med. source
Not checked in the free run.
- cites [66] Buss, 2022, Characterization of AAV-mediated dorsal root ganglionopathy, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationPrevious studies showed upregulation of MHCI protein 4 days after striatal injection of AAV9 or AAV2 in rats and upregulation of MHCI mRNA in mouse cortical microglia 3 days post AAV injection.
“These findings from mouse cortex align well with previous studies showing upregulation of MHCI protein 4 days after striatal injection of AAV9 or AAV2 in rats80,81 and upregulation of MHCI mRNA in mouse cortical microglia 3 days post AAV injection.82”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [80] Peden, 2009, Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented, Mol. Ther. source
Not checked in the free run.
- cites [81] Yang, 2013, Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain, PLoS One
Not checked in the free run.
- cites [82] Brown, 2021, Deep parallel characterization of AAV tropism and AAV-mediated transcriptional changes via single-cell RNA sequencing, bioRxiv
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationOverexpression of SMN1 in a spinal muscular atrophy mouse model causes a toxic gain of function.
“Additionally, overexpression of SMN1 in a spinal muscular atrophy mouse model causes a toxic gain of function.67”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [67] Van Alstyne, 2021, Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit, Nat. Neurosci. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationBroadly active cis-regulatory elements are correlated with dose-dependent, cell-type-specific toxicity after subretinal injection of AAV8, AAV5, or AAV2 in mice, and toxicity is still observed with AAVs that encode no transgene.
“Broadly active cis-regulatory elements are correlated with dose-dependent, cell-type-specific toxicity after subretinal injection of AAV8, AAV5, or AAV2 in mice, and toxicity is still observed with AAVs that encode no transgene.36”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [36] Xiong, 2019, AAV cis-regulatory sequences are correlated with ocular toxicity, Proc. Natl. Acad. Sci. USA source
Not checked in the free run.
May combine two claims.
Interpretationown dataTransgene expression is neither necessary nor sufficient for AAV-associated dendritic loss.
“Together, these findings demonstrate that transgene expression is neither necessary nor sufficient for AAV-associated dendritic loss.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAll data collection and analysis were performed by observers who were blinded to treatment.
“All data collection and analysis were performed by observers who were blinded to treatment.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationElectroporating only AAV's single-stranded DNA inverted terminal repeats (ITRs) into progenitor cells in vitro recapitulates dose-dependent loss of neural progenitor cells and immature adult-born dentate granule cells following injection of AAV into dentate gyrus.
“A recent study showed that electroporating only AAV’s single-stranded DNA inverted terminal repeats (ITRs) into progenitor cells in vitro recapitulates dose-dependent loss of neural progenitor cells and immature adult-born dentate granule cells following injection of AAV into dentate gyrus.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [63] Johnston, 2021, AAV ablates neurogenesis in the adult murine hippocampus, eLife source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationAAV-mediated gene delivery has been associated with neurotoxicity in specific cell populations, some of which can be attributed to the overexpressed transgene.
“Despite an overall strong safety profile, AAV-mediated gene delivery has been associated with neurotoxicity in specific cell populations, some of which can be attributed to the overexpressed transgene.”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [38] Hordeaux, 2018, Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
- cites [39] Hordeaux, 2020, MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates, Sci. Transl. Med. source
Not checked in the free run.
- cites [66] Buss, 2022, Characterization of AAV-mediated dorsal root ganglionopathy, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
- cites [67] Van Alstyne, 2021, Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit, Nat. Neurosci. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationA growing number of immune proteins have been identified that play central roles in neuronal homeostasis, where they negatively regulate neurite length, dendritic complexity, and synaptic transmission, and many are upregulated by TLR9.
“A growing number of immune proteins have been identified that play central roles in neuronal homeostasis, where they negatively regulate neurite length, dendritic complexity, and synaptic transmission,20,21,22,23,24,25,26,27,28,29,45,46,48,72,73,74,75,76,77,78,79 and many are upregulated by TLR9.”
Quote in the paperNot a substantial claim0 of 10 sources checked- cites [20] Datwani, 2009, Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity, Neuron source
Not checked in the free run.
- cites [21] Huh, 2000, Functional requirement for class I MHC in CNS development and plasticity, Science source
Not checked in the free run.
- cites [22] Lee, 2014, Synapse elimination and learning rules co-regulated by MHC class I H2-D b, Nature source
Not checked in the free run.
- cites [23] Schafer, 2012, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner, Neuron source
Not checked in the free run.
- cites [24] Stevens, 2007, The classical complement cascade mediates CNS synapse elimination, Cell source
Not checked in the free run.
- cites [25] Yilmaz, 2021, Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice, Nat. Neurosci. source
Not checked in the free run.
- cites [26] Dixon-Salazar, 2014, MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling, J. Neurosci. source
Not checked in the free run.
- cites [27] Glynn, 2011, MHCI negatively regulates synapse density during the establishment of cortical connections, Nat. Neurosci. source
Not checked in the free run.
- cites [28] Hu, 2020, MiR34a Regulates Neuronal MHC Class I Molecules and Promotes Primary Hippocampal Neuron Dendritic Growth and Branching, Front. Cell. Neurosci. source
Not checked in the free run.
- cites [29] Shen, 2019, MHC Class I Molecules and PirB Shape Neuronal Morphology by Affecting the Dendritic Arborization of Cortical Neurons, Neurochem. Res. source
Not checked in the free run.
May combine two claims.
Interpretationown dataAAV-mediated gene delivery is associated with significant loss of dendritic complexity, changes in the functional properties of synapses, and upregulation of many immune proteins that maintain normal neuronal structure and function in the healthy nervous system.
“The current results show that AAV-mediated gene delivery is associated with significant loss of dendritic complexity, changes in the functional properties of synapses, and upregulation of many immune proteins that maintain normal neuronal structure and function in the healthy nervous system”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductreasoningAnimals that received AAV2/1-pCAG-FLEX-EGFP-WPRE did not receive CRE recombinase and therefore should not express EGFP.
“Animals that received the AAV2/1-pCAG-FLEX-EGFP-WPRE virus did not receive any form of CRE recombinase and therefore should not express EGFP.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenA Shapiro-Wilk test was performed to ensure data were normally distributed.
“For all datasets, a Shapiro-Wilk test was performed to ensure data were normally distributed, and a two-tailed Grubb’s test was used to identify outliers.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAll SO analyses were performed by investigators blinded to condition.
“All SO analyses were performed by investigators blinded to condition.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationRabbits and rats are more sensitive than monkeys to the TLR3 agonist rintatolimod, while mice are far more tolerant than humans to several TLR agonists, including the TLR4 ligand endotoxin (lipopolysaccharide).
“For example, rabbits and rats are more sensitive than monkeys to the TLR3 agonist rintatolimod,83 while mice are far more tolerant than humans to several TLR agonists, including the TLR4 ligand endotoxin84 (lipopolysaccharide).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [83] Mitchell, 2014, Discordant biological and toxicological species responses to TLR3 activation, Am. J. Pathol. source
Not checked in the free run.
- cites [84] Copeland, 2005, Acute inflammatory response to endotoxin in mice and humans, Clin. Diagn. Lab. Immunol.
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataA subset of experiments included a washout period to confirm that sEPSC amplitude recovered after removing NASPM.
“A subset of experiments also included a washout period to confirm that sEPSC amplitude recovered after removing NASPM.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationA synthetic TLR9 agonist causes neurite loss in organotypic cortico-hippocampal slices, which lack a source of infiltrating immune cells.
“However, a synthetic TLR9 agonist causes neurite loss in organotypic cortico-hippocampal slices,87 which lack a source of infiltrating immune cells”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [87] Iliev, 2004, Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9), FASEB J. source
Not checked in the free run.
May combine two claims.
Interpretationown dataRemote injection can prevent dendritic damage while permitting local transgene expression in projection fibers.
“suggesting that remote injection can prevent dendritic damage while permitting local transgene expression in projection fibers.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThe neuronal effects of AAV are caused by unmethylated CpG motifs, which are TLR9 ligands.
“suggesting they are caused by unmethylated CpG motifs, which are TLR9 ligands.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductnone givenVirus preps were treated with turbonuclease to minimize viral, host, and plasmid DNA impurities.
“Virus preps were treated with turbonuclease to minimize viral, host, and plasmid DNA impurities.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
Study design and conductown dataAn investigator blinded to treatment traced cells, quantified total dendritic length and total nodes, and performed Sholl analyses on labeled neurons.
“An investigator blinded to treatment traced cells, quantified total dendritic length and total nodes, and performed Sholl analyses on labeled neurons using the Simple Neurite Tracer Plugin in ImageJ FIJI.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductreasoningIn current studies using AAV8-mCherry, DiO-labeled neurons that did not show detectable mCherry expression were exclusively imaged.
“In the current studies using AAV8-mCherry, we exclusively imaged DiO-labeled neurons that did not show detectable mCherry expression”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Interpretationnone givenThe appropriate multiplicity of infection will vary depending on each unique combination of capsid serotype, promoter, encoded transgene, model, and route of administration.
“The appropriate multiplicity of infection will vary depending on each unique combination of capsid serotype, promoter, encoded transgene, model, and route of administration.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductreasoningVirus preps were endotoxin negative.
“Viruses were prepared using endotoxin-free plasmid prep kits, and virus preps were endotoxin negative.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenA two-tailed Grubb's test was used to identify outliers.
“For all datasets, a Shapiro-Wilk test was performed to ensure data were normally distributed, and a two-tailed Grubb’s test was used to identify outliers.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThree investigators blinded to treatment counted DAPI+ cells within a consistently sized boxed area using ImageJ in layers I, II/III, IV, V, and VI.
“Three investigators blinded to treatment counted DAPI+ cells within a consistently sized boxed area using ImageJ in layers I, II/III, IV, V, and VI.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationCell death associated with high concentrations of AAV was partially attenuated by repeated treatment with antibodies against cytotoxic T lymphocytes.
“Cell death associated with high concentrations of AAV was partially attenuated by repeated treatment with antibodies against cytotoxic T lymphocytes.60”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [60] Guo, 2023, High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Premisecitation18s rRNA was the least affected among tested genes after viral infection.
“Kuchipudi et al.97 found that 18s rRNA was the least affected among tested genes, and we therefore used 18s rRNA as a reference gene for this study.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Kuchipudi et al.97 Kuchipudi, 2012, 18S rRNA is a reliable normalisation gene for real time PCR based on influenza virus infected cells, Virol. J. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductreasoningTo reduce type I errors arising from multiple comparisons, only virus-untreated, virus-sham, and sham-untreated comparisons were performed.
“To reduce type I errors arising from multiple comparisons, only virus-untreated, virus-sham, and sham-untreated comparisons were performed.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisereasoningODN 2088 and many other TLR9 inhibitors are short oligonucleotides, they can be introduced into host cells as part of the viral genome, in cis.
“Because ODN 2088 and many other TLR9 inhibitors are short oligonucleotides, they can be introduced into host cells as part of the viral genome, in cis, an approach that has recently been used to reduce or delay AAV-induced toxicity in the retina in pigs and macaques, respectively.61”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [61] Chan, 2021, Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses, Sci. Transl. Med. source
Not checked in the free run.
- Rests on an assumption: ODN 2088 and many other TLR9 inhibitors are short oligonucleotides that can be introduced into host cells as part of the viral genome, in cis.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataNo-primary controls show lack of non-specific secondary antibody binding in lanes containing protein samples for all of the secondary antibodies used.
“No-primary controls show lack of non-specific secondary antibody binding in lanes containing protein samples for all of the secondary antibodies used (Figure S6B).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationProminent differences in TLR responses exist across mammals, including differences in the timing and magnitude of TLR-mediated signaling.
“Prominent differences in TLR responses exist across mammals, including differences in the timing and magnitude of TLR-mediated signaling.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenMultiple exposures were taken, and appropriate exposures were used to quantify densitometry within the linear range of assay sensitivity.
“Multiple exposures were taken, and appropriate exposures were used to quantify densitometry within the linear range of assay sensitivity.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationInjection of a large volume of concentrated AAV (1 μL of 1 × 1013 vg per mL) can cause infiltration of cytotoxic T cells and associated neurotoxicity, changes that are averted by injecting the same volume of a lower titer virus (1 × 1011 vg per mL).
“For example, injection of a large volume of concentrated AAV (1 μL of 1 × 1013 vg per mL) can cause infiltration of cytotoxic T cells and associated neurotoxicity, changes that are averted by injecting the same volume of a lower titer virus (1 × 1011 vg per mL).60”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [60] Guo, 2023, High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataLack of EGFP was confirmed by confocal immunofluorescence microscopy and immunoblotting.
“Lack of EGFP was confirmed by both confocal immunofluorescence microscopy (Figures 1B and S1G) and by using immunoblotting to amplify EGFP signals (Figure 4A).”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Study design and conductnone givenCells selected for tracing were randomized into a cohort and labeled before being uploaded to a single folder for blinded investigators.
“The contralateral and ipsilateral cells that were selected for tracing were randomized into a cohort and labeled as “Cell 1,” “Cell 2,” and so forth before being uploaded to a single folder for blinded investigators.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataLack of bands in negative control lanes indicates absence of primer dimers.
“Lack of bands in these lanes indicates absence of primer dimers (Figure S6A).”
Quote in the paperNot a substantial claimMay combine two claims.
Study design and conductown dataNotching fixed sections does not alter dendritic complexity because both vehicle control and AAV8-hSyn-mCherry 1:20 titer cohorts were notched, and dendritic complexity is not different from untreated controls in these groups.
“Notching fixed sections does not alter dendritic complexity because both vehicle control and AAV8-hSyn-mCherry 1:20 titer cohorts were notched, and dendritic complexity is not different from untreated controls in these groups.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThese studies reveal unexpected effects of AAV-mediated gene delivery on neuronal structure and function and identify the immune response to the AAV genome as the triggering event.
“Together, these studies reveal unexpected effects of AAV-mediated gene delivery on neuronal structure and function and identify the immune response to the AAV genome as the triggering event.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenMelt curves were calculated to establish the quality of the data, and any flagged data were omitted.
“Melt curves were calculated to establish the quality of the data, and any flagged data were omitted.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationIntraparenchymal administration of high doses of AAV9 causes significant neuronal death and titer-dependent infiltration of peripheral immune cells.
“A recent study found that intraparenchymal administration of high doses of AAV9, which causes significant neuronal death, causes titer-dependent infiltration of peripheral immune cells.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [60] Guo, 2023, High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain, Mol. Ther. Methods Clin. Dev. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductreasoningOne-tailed t tests were used to analyze exogenous mCherry mRNA levels because changes in only one direction (rises) are possible from baseline.
“One-tailed t tests were used to analyze exogenous mCherry mRNA levels because changes in only one direction (rises) are possible from baseline.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
The AAV genome is rich in unmethylated CpG DNA.
“The AAV genome is rich in unmethylated CpG DNA”
“One feature that is shared by essentially all AAVs is a genome that is rich in unmethylated CpG DNA motifs”
The paper relies on this without support.
Unmethylated CpG DNA is recognized by TLR9.
“which is recognized by the innate immunoreceptor Toll-like receptor 9 (TLR9)”
“which are detected by the innate immunoreceptor TLR9”
The paper relies on this without support.
The AAV genome is not rapidly cleared by the immune response in the CNS.
“Although the AAV genome is not rapidly cleared by the immune response in the CNS”
The paper relies on this without support.
Unmethylated CpG motifs are a core feature of the AAV genome.
“Since unmethylated CpGs are a core feature of the AAV genome”
The paper relies on this without support.
TLR9 can detect unmethylated CpG DNA from diverse sources.
“Because TLR9 can detect unmethylated CpG DNA from diverse sources”
The paper relies on this without support.
Dendritic morphology powerfully influences integration and other emergent properties that arise due to the electrical separation of synapses.
“Dendritic morphology powerfully influences integration and other emergent properties that arise due to the electrical separation of synapses”
The paper relies on this without support.
AAV genomes are present in both experimental and control conditions when AAVs encoding fluorescent tracers or unexpressed transgenes are used as negative controls.
“since AAV genomes are present in both experimental and control conditions.”
The paper relies on this without support.
Many of the deleterious and efficacy-limiting immune responses to AAV in clinical trials were not predicted by preclinical work in animal models.
“Notably, many of the deleterious and efficacy-limiting immune responses to AAV in clinical trials were not predicted by preclinical work in animal models.”
The paper relies on this without support.
A lower number of viral genomes may, in some cases, be insufficient to drive robust transgene expression.
“However, a lower number of vg may, in some cases, be insufficient to drive robust transgene expression.”
The paper relies on this without support.
ODN 2088 and many other TLR9 inhibitors are short oligonucleotides that can be introduced into host cells as part of the viral genome, in cis.
“Because ODN 2088 and many other TLR9 inhibitors are short oligonucleotides, they can be introduced into host cells as part of the viral genome, in cis”
The authors state this as an assumption.
The data have equal variance across groups.
“Two-tailed unpaired t tests assuming equal variance were used for all comparisons.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TLR9-dependent reduction of dendritic length and complexity and disruption of synaptic transmission occurred in mouse somatosensory cortex after AAV gene transfer, accompanied by changes in AMPA receptor subunit composition and prevented by TLR9 blockade.
“Another recent investigation reports TLR9-dependent reduction of dendritic length and complexity and disruption of synaptic transmission in mouse somatosensory cortex in response to AAV gene transfer, which was accompanied by changes in AMPA receptor subunit composition but could be prevented by TLR9 blockade.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Statistical methods say all comparisons used two-tailed t tests, then specify one-tailed tests
MinorThe statement that two-tailed t tests were used for all comparisons conflicts with the later statement that exogenous mCherry mRNA was analyzed using one-tailed t tests.
“Two-tailed unpaired t tests assuming equal variance were used for all comparisons.”
“One-tailed t tests were used to analyze exogenous mCherry mRNA levels because changes in only one direction (rises) are possible from baseline.”
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · see citing works
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089 · see citing works
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · see citing works
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · see citing works
Statistical analysis of real-time PCR data
Yuan, J. S., Reed, A., Chen, F., & Stewart, C. N. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-85 · Cited by 2,192 · see citing works
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · see citing works
Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578 · see citing works
Geiger, J. R. P., Melcher, T., Koh, D.-S., Sakmann, B., Seeburg, P. H., Jonas, P., & Monyer, H. (1995) · Neuron · doi:10.1016/0896-6273(95)90076-4 · Cited by 1,260 · see citing works
Functional requirement for class I MHC in CNS development and plasticity
Huh, G. S., Boulanger, L. M., Du, H., Riquelme, P. A., Brotz, T. M., & Shatz, C. J. (2000) · Science · doi:10.1126/science.290.5499.2155 · Cited by 828 · see citing works
Self-citationHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814 · see citing works
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · see citing works
Nakazawa, T., Komai, S., Tezuka, T., Hisatsune, C., Umemori, H., Semba, K., Mishina, M., Manabe, T., & Yamamoto, T. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008085200 · Cited by 466 · see citing works
Synaptic activity at calcium-permeable AMPA receptors induces a switch in receptor subtype
Liu, S. J., & Cull-Candy, S. G. (2000) · Nature · doi:10.1038/35013064 · Cited by 451 · see citing works
Acute Inflammatory Response to Endotoxin in Mice and Humans
Copeland, S., Warren, H. S., Lowry, S. F., Calvano, S. E., & Remick, D. G. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.1.60-67.2005 · Cited by 427 · see citing works
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420 · see citing works
Immunogenicity and toxicity of AAV gene therapy
Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402 · see citing works
Onasemnogene Abeparvovec: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01162-5 · Cited by 337 · cited 2× · see citing works
“…clinically to restore endogenous protein function in the nervous system to treat Leber ’ s congenital amaurosis 2 2,3 and spinal muscular atrophy, 4,5 and AAV-based clinical trials are under way to treat numerous other disorders of the nervous system, including Alzheimer ’ s disease, Canavan ’ s…”
Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiments
Ansari, A. M., Ahmed, A. K., Matsangos, A. E., Lay, F., Born, L. J., Marti, G. P., Harmon, J. W., & Sun, Z. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9670-8 · Cited by 324 · see citing works
Regulation of CNS synapses by neuronal MHC class I
Goddard, C. A., Butts, D. A., & Shatz, C. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702023104 · Cited by 322 · see citing works
Yilmaz, M., Yalcin, E., Presumey, J., Aw, E., Ma, M., Whelan, C. W., Stevens, B., McCarroll, S. A., & Carroll, M. C. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00763-8 · Cited by 321 · see citing works
Köhr, G., & Seeburg, P. H. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021320 · Cited by 310 · see citing works
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291 · see citing works
CXCR3-Dependent Microglial Recruitment Is Essential for Dendrite Loss after Brain Lesion
Rappert, A., Bechmann, I., Pivneva, T., Mahlo, J., Biber, K., Nolte, C., Kovac, A. D., Gerard, C., Boddeke, H. W. G. M., Nitsch, R., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2451-04.2004 · Cited by 259 · see citing works
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · see citing works
AAV <i>cis</i> -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249 · see citing works
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · see citing works
Synapse elimination and learning rules co-regulated by MHC class I H2-Db
Lee, H., Brott, B. K., Kirkby, L. A., Adelson, J. D., Cheng, S., Feller, M. B., Datwani, A., & Shatz, C. J. (2014) · Nature · doi:10.1038/nature13154 · Cited by 228 · see citing works
Wright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219 · see citing works
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · cited 2× · see citing works
“63 It will be of interest to determine whether this AAV-induced impairment of neurogenesis, like AAV-associated cell death in the retina 61 and AAV-induced dendritic loss and changes in AMPA receptor subunit composition in cortex seen here, can be improved by inhibition of TLR9.”
Tardieu, M., Zérah, M., Gougeon, M.-L., Ausseil, J., de Bournonville, S., Husson, B., Zafeiriou, D., Parenti, G., Bourget, P., Poirier, B., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30169-2 · Cited by 214 · see citing works
Classical MHCI Molecules Regulate Retinogeniculate Refinement and Limit Ocular Dominance Plasticity
Datwani, A., McConnell, M. J., Kanold, P. O., Micheva, K. D., Busse, B., Shamloo, M., Smith, S. J., & Shatz, C. J. (2009) · Neuron · doi:10.1016/j.neuron.2009.10.015 · Cited by 212 · see citing works
Normal cognitive and social development require posterior cerebellar activity
Badura, A., Verpeut, J. L., Metzger, J. W., Pereira, T. D., Pisano, T. J., Deverett, B., Bakshinskaya, D. E., & Wang, S. S.-H. (2018) · eLife · doi:10.7554/elife.36401 · Cited by 205 · see citing works
Self-citationMHCI negatively regulates synapse density during the establishment of cortical connections
Glynn, M. W., Elmer, B. M., Garay, P. A., Liu, X.-B., Needleman, L. A., El-Sabeawy, F., & McAllister, A. K. (2011) · Nature Neuroscience · doi:10.1038/nn.2764 · Cited by 198 · see citing works
A monomeric red fluorescent protein with low cytotoxicity
Shemiakina, I. I., Ermakova, G. V., Cranfill, P. J. C., Baird, M. A., Evans, R. A., Souslova, E. A., Staroverov, D. B., Gorokhovatsky, A. Y., Putintseva, E. V., Gorodnicheva, T. V., et al. (2012) · Nature Communications · doi:10.1038/ncomms2208 · Cited by 197 · see citing works
Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)
Iliev, A. I., Stringaris, A. K., Nau, R., & Neumann, H. (2004) · The FASEB Journal · doi:10.1096/fj.03-0670fje · Cited by 192 · see citing works
Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene
Kojima, N., Wang, J., Mansuy, I. M., Grant, S. G. N., Mayford, M. R., & Kandel, E. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4761 · Cited by 188 · see citing works
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Van Alstyne, M., Tattoli, I., Delestrée, N., Recinos, Y., Workman, E., Shihabuddin, L. S., Zhang, C., Mentis, G. Z., & Pellizzoni, L. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00827-3 · Cited by 188 · see citing works
Calcium Permeable-AMPA Receptors and Excitotoxicity in Neurological Disorders
Guo, C., & Ma, Y. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.711564 · Cited by 184 · see citing works
Achieving High-Frequency Optical Control of Synaptic Transmission
Jackman, S. L., Beneduce, B. M., Drew, I. R., & Regehr, W. G. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4694-13.2014 · Cited by 182 · see citing works
Innate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178 · see citing works
Hordeaux, J., Buza, E. L., Jeffrey, B., Song, C., Jahan, T., Yuan, Y., Zhu, Y., Bell, P., Li, M., Chichester, J. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9188 · Cited by 174 · see citing works
Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2013.9 · Cited by 165 · see citing works
18S rRNAis a reliable normalisation gene for real time PCR based on influenza virus infected cells
Kuchipudi, S. V., Tellabati, M., Nelli, R. K., White, G. A., Baquero-Pérez, B., Sebastian, S., Slomka, M. J., Brookes, S. M., Brown, I. H., Dunham, S. P., et al. (2012) · Virology Journal · doi:10.1186/1743-422x-9-230 · Cited by 165 · see citing works
Adeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148 · see citing works
Expression of Toll-Like Receptors in the Developing Brain
Kaul, D., Habbel, P., Derkow, K., Krüger, C., Franzoni, E., Wulczyn, F. G., Bereswill, S., Nitsch, R., Schott, E., Veh, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037767 · Cited by 141 · see citing works
Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137 · see citing works
Neuroprotection from Stroke in the Absence of MHCI or PirB
Steinmetz, J. D., Barreto, G. E., Xu, L., Kim, T., Brott, B. K., Ouyang, Y., Naserke, T., Djurisic, M. R., Xiong, X., Shatz, C. J., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.01.020 · Cited by 135 · see citing works
Doi, Y., Mizuno, T., Maki, Y., Jin, S., Mizoguchi, H., Ikeyama, M., Doi, M., Michikawa, M., Takeuchi, H., & Suzumura, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090418 · Cited by 135 · see citing works
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131 · see citing works
Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems
Chen, X., Kumar, S. R., Adams, C. D., Yang, D., Wang, T., Wolfe, D. A., Arokiaraj, C. M., Ngo, V., Campos, L., Griffiths, J. A., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.05.003 · Cited by 131 · see citing works
First AAV gene therapy poised for landmark approval
Smalley, E. (2017) · Nature Biotechnology · doi:10.1038/nbt1117-998 · Cited by 121 · see citing works
Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020) · Brain Sciences · doi:10.3390/brainsci10020119 · Cited by 112 · see citing works
The Role of Excitotoxic Programmed Necrosis in Acute Brain Injury
Fujikawa, D. G. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.03.004 · Cited by 110 · see citing works
Butchi, N. B., Du, M., & Peterson, K. E. (2010) · Glia · doi:10.1002/glia.20952 · Cited by 109 · see citing works
Ciesielska, A., Hadaczek, P., Mittermeyer, G., Zhou, S., Wright, J. F., Bankiewicz, K. S., & Forsayeth, J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.167 · Cited by 108 · see citing works
The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages
Grassin‐Delyle, S., Abrial, C., Salvator, H., Brollo, M., Naline, E., & Devillier, P. (2018) · Journal of Innate Immunity · doi:10.1159/000494463 · Cited by 106 · see citing works
Hordeaux, J., Hinderer, C., Goode, T., Katz, N., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.003 · Cited by 105 · see citing works
Hyperammonemia in gene-targeted mice lacking functional hepatic glutamine synthetase
Qvartskhava, N., Lang, P. A., Görg, B., Pozdeev, V. I., Ortiz, M. P., Lang, K. S., Bidmon, H. J., Lang, E., Leibrock, C. B., Herebian, D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423968112 · Cited by 98 · see citing works
Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma
Riihilä, P., Nissinen, L. M., Farshchian, M., Kallajoki, M. A., Kivisaari, A., Meri, S., Grenman, R. A., Peltonen, S. A., Peltonen, J. T. K., Pihlajaniemi, T. A., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.006 · Cited by 92 · see citing works
Elmer, B. M., Estes, M. L., Barrow, S. L., & McAllister, A. K. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2366-13.2013 · Cited by 88 · see citing works
AAV ablates neurogenesis in the adult murine hippocampus
Johnston, S., Parylak, S. L., Kim, S., Mac, N., Lim, C., Gallina, I., Bloyd, C., Newberry, A., Saavedra, C. D., Novak, O., et al. (2021) · eLife · doi:10.7554/elife.59291 · Cited by 87 · see citing works
Reyes‐Sandoval, A., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.008 · Cited by 85 · see citing works
Characterization of AAV-mediated dorsal root ganglionopathy
Buss, N., Lanigan, L., Zeller, J., Cissell, D., Metea, M., Adams, E., Higgins, M., Kim, K. H., Budzynski, E., Yang, L., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.013 · Cited by 81 · see citing works
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80 · see citing works
Enhanced synaptic transmission and reduced threshold for LTP induction in fyn‐transgenic mice
Lü, Y.-F., Kojima, N., Tomizawa, K., Moriwaki, A., Matsushita, M., Obata, K., & Matsui, H. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00407.x · Cited by 77 · see citing works
Pasch, M. C., van den Bosch, N. H. A., Bos, J. D., Asghar, S. S., & Daha, M. R. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00841.x · Cited by 77 · see citing works
Timmers, A. M., Newmark, J. A., Turunen, H. T., Farivar, T., Liu, J., Song, C., Ye, G.-J., Pennock, S., Gaskin, C., Knop, D. R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.144 · Cited by 77 · see citing works
Sondhi, D., Kaminsky, S. M., Hackett, N. R., Pagovich, O. E., Rosenberg, J. B., De, B. P., Chen, A., Van de Graaf, B., Mezey, J. G., Mammen, G. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5413 · Cited by 72 · see citing works
Fischer, K. B., Collins, H. K., & Callaway, E. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915974116 · Cited by 69 · see citing works
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67 · see citing works
Kuchtey, J., Chefalo, P. J., Gray, R. C., Ramachandra, L., & Harding, C. V. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2244 · Cited by 66 · see citing works
Quantification of CpG motifs in rAAV genomes: Avoiding the toll
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.006 · Cited by 65 · see citing works
TLR7 and TLR9 Trigger Distinct Neuroinflammatory Responses in the CNS
Butchi, N. B., Woods, T. A., Du, M., Morgan, T. W., & Peterson, K. E. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.011 · Cited by 59 · see citing works
Brown, D. A., Altermatt, M., Dobreva, T., Chen, S., Wang, A. Z., Thomson, M. W., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 58 · see citing works
Hawash, M. B. F., Sanz-Remón, J., Grenier, J.-C., Kohn, J., Yotova, V., Johnson, Z., Lanford, R. E., Brinkworth, J. F., & Barreiro, L. B. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015855118 · Cited by 56 · see citing works
Humoral immune responses to <scp>AAV</scp> gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52 · see citing works
MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling
Dixon-Salazar, T. J., Fourgeaud, L., Tyler, C. M., Poole, J. R., Park, J. J., & Boulanger, L. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4642-12.2014 · Cited by 51 · see citing works
Self-citationMiyake, K., Miyake, N., Yamazaki, Y., Shimada, T., & Hirai, Y. (2012) · Journal of Nippon Medical School · doi:10.1272/jnms.79.394 · Cited by 48 · see citing works
Guo, Y., Chen, J., Ji, W., Xu, L., Xie, Y., He, S., Lai, C., Hou, K., Li, Z., Chen, G., et al. (2023) · Molecular Therapy Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.021 · Cited by 47 · see citing works
Role of immune molecules in the establishment and plasticity of glutamatergic synapses
Fourgeaud, L., & Boulanger, L. M. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07342.x · Cited by 44 · see citing works
Self-citationPeden, C. S., Manfredsson, F. P., Reimsnider, S. K., Poirier, A. E., Burger, C., Muzyczka, N., & Mandel, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.284 · Cited by 44 · see citing works
Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
Chandler, L. C., McClements, M. E., Yusuf, I. H., Martinez-Fernandez de la Camara, C., MacLaren, R. E., & Xue, K. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.011 · Cited by 43 · see citing works
Mangsbo, S. M., Sanchez, J., Anger, K., Lambris, J. D., Ekdahl, K. N., Loskog, A. S., Nilsson, B., & Tötterman, T. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902374 · Cited by 42 · see citing works
Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice
Babus, L. W., Little, E. M., Keenoy, K. E., Minami, S., Chen, E., Song, J. M., Caviness, J., Koo, S. Y., Pak, D. T. S., Rebeck, G. W., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.07.059 · Cited by 39 · see citing works
Off-Target Expression of Cre-Dependent Adeno-Associated Viruses in Wild-Type C57BL/6J Mice
Botterill, J. J., Khlaifia, A., Walters, B. J., Brimble, M. A., Scharfman, H. E., & Arruda-Carvalho, M. (2021) · eNeuro · doi:10.1523/eneuro.0363-21.2021 · Cited by 38 · see citing works
Universal features of dendrites through centripetal branch ordering
Alexandra, V., Effenberger, F., Muellerleile, J., & Cuntz, H. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005615 · Cited by 37 · see citing works
Bats, C., Farrant, M., & Cull-Candy, S. G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.037 · Cited by 34 · see citing works
Li, L., Ni, L., Heary, R. F., & Elkabes, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01748-x · Cited by 34 · see citing works
Wu, Z.-P., Washburn, L. R., Bilousova, T. V., Boudzinskaia, M., Escande‐Beillard, N., Querubin, J., Dang, H. N., Xie, C.-W., Tian, J., & Kaufman, D. L. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.09.009 · Cited by 32 · see citing works
Washburn, L. R., Zekzer, D., Eitan, S., Lu, Y., Dang, H. N., Middleton, B., Evans, C. J., Tian, J., & Kaufman, D. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018439 · Cited by 28 · see citing works
Discordant biological and toxicological species responses to TLR3 activation
Mitchell, W. M., Nicodemus, C. F., Carter, W. A., Horvath, J. C., & Strayer, D. R. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.006 · Cited by 27 · see citing works
Lin, N., Geng, Y., Lovett-Barron, M., Niu, X., Deng, M., Wang, L., Ataie, N., Sens, A., Ng, H. L., Chen, S., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.893468 · Cited by 25 · see citing works
Hu, Y., Pei, W., Hu, Y., Li, P., Sun, C., Du, J., Zhang, Y., Miao, F., Zhang, A., Shen, Y., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.573208 · Cited by 18 · see citing works
Shen, Y., Zhao, H., Li, P., Peng, Y., Cui, P., Miao, F., Zhang, Y., Zhang, A., & Zhang, J. (2019) · Neurochemical Research · doi:10.1007/s11064-018-2676-7 · Cited by 14 · see citing works
Brown, D. A., Altermatt, M., Dobreva, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.25.449955 · Cited by 11 · see citing works
Yang, C., Yang, W., Chen, S., Bao-feng, M., Li, B., Lu, T., Qu, T., Klein, R. L., Zhao, L., & Duan, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063876 · Cited by 10 · see citing works
Lim, W., Kwan, J. L., Goh, L. K., Beuerman, R. W., & Barathi, V. A. (2012) · Europe PMC (PubMed Central) · Cited by 8 · see citing works
Activation of CpG-ODN-Induced TLR9 Signaling Inhibited by Interleukin-37 in U937 Human Macrophages
Kim, S., Choe, J., & Park, K.-Y. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2021.62.11.1023 · Cited by 8 · see citing works
Savani, R. H., Park, E., Busannagari, N., Lu, Y., Kwon, H., Wang, L., & Pang, Z. P. (2024) · Bioscience Reports · doi:10.1042/bsr20231846 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50 · see citing works
Neuropharmacology of synaptic plasticity: pathways to cognitive resilience in healthy aging
Goel, F., Singh, P., Nand, S., & Yadav, D. K. (2026) · 3 Biotech · doi:10.1007/s13205-025-04673-z · Cited by 23 · see citing works
Analyzing efficacy, stability, and safety of AAV-mediated optogenetic hearing restoration in mice
Bali, B., Gruber-Dujardin, E., Kusch, K., Rankovic, V., & Moser, T. (2022) · Life Science Alliance · doi:10.26508/lsa.202101338 · Cited by 23 · see citing works
Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 13 · see citing works
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
Xu, Y., Bai, X., Lin, J., Lu, K., Weng, S., Wu, Y., Liu, S., Li, H., Wu, Z., Chen, G., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101420 · Cited by 13 · see citing works
Kumagai, S., Nakajima, T., & Muramatsu, S. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2386339 · Cited by 11 · see citing works
From synaptic dynamics to cognitive decline: Molecular insights into neuroplasticity
C, B. K., & G., P. P. C. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123937 · Cited by 6 · see citing works
Fan, Y., Guo, X., Lyu, J., Huang, T., Zhang, C., Wang, X., Cui, X., Li, C., & He, Y. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.176725 · Cited by 5 · see citing works
Early postnatal expression mitigates immune responses to Cas9 in the murine central nervous system
Duba-Kiss, R., & Hampson, D. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101536 · Cited by 5 · see citing works
Gene Therapy for Inherited Liver Disease: To Add or to Edit
Chen, Y., van Til, N. P., & Bosma, P. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312514 · Cited by 4 · see citing works
Ni, X., Liu, H., Ji, X., Chen, Z., Chen, X., Luo, Y., Chen, W., & Yang, S. (2025) · Acta Oto-Laryngologica · doi:10.1080/00016489.2025.2492366 · Cited by 3 · see citing works
Santoscoy, M. C., Espinoza, P., Hanlon, K. S., Yang, L., Nieland, L., Ng, C., Badr, C. E., Hickman, S. E., de la Cruz, D., Griciuc, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614546 · Cited by 2 · see citing works
Species barriers in AAV tropism: mechanisms, models, and emerging solutions for clinical translation
Xu, X. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15939 · Cited by 1 · see citing works
Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations
Dayma, K., & Upadhyay, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.030 · Cited by 1 · see citing works
Xu, Y., Bai, X.-N., Lin, J., Lu, K., Weng, S., Wu, Y., Liu, S., Li, W., Chen, G., & Li, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.15.612566 · Cited by 1 · see citing works
Hydroxychloroquine decouples reactogenicity from efficacy in mRNA and viral-vector gene deliveryPreprint
Lainšček, D., Malenšek, Š., Golob-Urbanc, A., Orehek, S., Bohinc, J., Keber, M. M., Sotošek, T., Esih, H., Forstnerič, V., Pečan, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.10.687670
Adeno-associated virus-induced neurotoxicity is prevented by CpG depletion
Dunn, C. E., Carvajal, B. V., Ma, J., Castaneda-Hernandez, G., Nguyen, A. V., Jung, C., Suriano, C. M., & Boulanger, L. M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201703
Self-citationGuo, Y., Huang, J., Zhang, Y., Huang, Y., Li, Z., Xie, Y., Cao, Y., Qian, K., Bai, F., Li, W., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.001
Ji, T., Zhang, Y., Zhao, J. J., Lu, Y., & Wang, C. (2026) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.70041
Ayon, A., Jalil, A., Egan, C., Ducos, B., Mailhes‐Hamon, C., Tangara, A., Mathieu, B., Bemelmans, A., Llano, I., Bourdieu, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.752944
Lainšček, D., Malenšek, Š., Forstnerič, V., Golob-Urbanc, A., Orehek, S., Bohinc, J., Keber, M. M., Sotošek, T., Esih, H., Pečan, P., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.033
- Authors
- Suriano, C. M., Kumar, N., Verpeut, J. L., Ma, J., Jung, C., Dunn, C. E., Carvajal, B. V., Nguyen, A. V., & Boulanger, L. M.
- Affiliations
- Montclair State University (US)
- Princeton University (US)
- Corresponding author
- Suriano, Christos M.
- Boulanger, Lisa M.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 32
- Issue
- 6
- Pages
- 1721-1738
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC11184335
- OpenAlex
- W4393371324
- Semantic Scholar
- 28bb6db576f6a3ec0eb56b8486599bbfdde156d8
- Cited by
- 21
- References
- 99
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 6 · 2022: 1
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Princeton University
- Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences
- National Institutes of Health (T32MH065214-11, TL1TR003019, T32GM007388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- adeno-associated virus, innate immune response, dendritic complexity, synaptic transmission, TLR9, CpG DNA, AMPA receptors, calcium-permeable AMPA receptors, GluA2, somatosensory cortex, neuroimmunology
- MeSH terms
- Dependovirus, Animals, Dendrites, Genetic Vectors, Immunity, Innate, Synaptic Transmission, Somatosensory Cortex, Genome, Viral, Receptors, AMPA, Toll-Like Receptor 9, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review